Please login to the form below
ulcerative colitis
This page shows the latest ulcerative colitis news and features for those working in and with pharma, biotech and healthcare.
Amgen’s biosimilar delivers impressive phase 3 results for psoriasis compared to Janssen’s Stelara
These patients are typically candidates for phototherapy or systemic therapy and also include those with moderately to severely active Crohn's disease and ulcerative colitis.
Latest news
-
Pfizer finalises $6.7bn acquisition of Arena Pharmaceuticals
This includes etrasimod, currently in development for a range of immuno-inflammatory diseases including Crohn’s Disease, ulcerative colitis, eosinophilic esophagitis, alopecia areata and atopic dermatitis. ... Previously, Arena has indicated that it
-
Pfizer buys Arena in $6.7bn deal to broaden immuno-inflammatory portfolio
The cash deal includes Arena’s lead candidate, etrasimod, which is currently in trials for ulcerative colitis, Crohn’s disease and atopic dermatitis. ... Its lead candidate, etrasimod – an oral, selective sphingosine 1-phosphate (S1P) receptor
-
Biosimilars boosted by FDA's landmark ruling for Boehringer’s Cyltezo
The FDA approval covers adult patients with forms of rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis and plaque psoriasis.
-
J&J and Pfizer quietly resolve Remicade biosimilar lawsuit
When it came the US approval covered six indications, including rheumatoid arthritis, ankylosing spondylitis, ulcerative colitis and Crohn's disease.
-
BMS’ Zeposia gains FDA approval in ulcerative colitis
to severely active ulcerative colitis (UC). ... We’re thrilled that our pursuit of transformative science in immunology may benefit patients in their ulcerative colitis treatment by introducing a new option that has a different mechanism of action
More from news
Approximately 23 fully matching, plus 130 partially matching documents found.
Latest Intelligence
-
Setting up for success in a post-Brexit, post-pandemic Britain
With a focus on inflammatory and fibrotic conditions, we have submitted a marketing application through our partnership with Gilead for a new treatment for ulcerative colitis (UC) to the MHRA in
-
Gut instincts lead Takeda to GI pipeline success
with Crohn’s disease or ulcerative colitis is expected to rise by around 25% by 2025, according to recent studies.
-
A snapshot of Microbiotica
These capabilities attract collaborations with leading groups from around the world to provide the clinical data and samples to feed the process, including a University of Adelaide ulcerative colitis FMT study. ... We know this has had an impact.
-
Taking a lean and careful approach
ulcerative colitis, type 1 diabetes and inflammatory bowel disease.
-
Making digital health personal
Personalisation: A case study. This case study is of a digital health support programme that improved persistence of people with ulcerative colitis.
More from intelligence
Approximately 0 fully matching, plus 15 partially matching documents found.
Latest appointments
-
Lorin Johnson joins Atlantic Healthcare board
Atlantic's lead asset, alicaforsen for the treatment of the inflammatory bowel diseases ulcerative colitis and pouchitis.
-
Ex J&J VP joins board of Immune
Its lead product candidate is bertilimumab, which is in clinical development for ulcerative colitis and Crohn's Disease as well as the rare skin condition bullous pemphigoid.
-
AstraZeneca veteran Deborah Hartman joins Avaxia
Will lead the development of AVX-470 in ulcerative colitis. Former AstraZeneca (AZ) vice president Dr Deborah Hartman has joined Avaxia Biologics as VP research, replacing Dan Tracey who retires. ... with active ulcerative colitis.
-
EMA’s Pharmacovigilance Risk Assessment Committee gains new members
Their respective alternates are Kirsten Myhr, from the Norwegian Board of Health, and Marco Greco, from the European Federation Crohn's and Ulcerative Colitis Associations.
More from appointments
Approximately 0 fully matching, plus 4 partially matching documents found.
Latest from PMHub
-
Insights from patients during the COVID-19 pandemic
We carried out a survey among patients who have any one of these conditions: chronic obstructive pulmonary disorder (COPD), ulcerative colitis (UC), Crohn’s disease (CD) and idiopathic pulmonary fibrosis (IPF).
-
July 2020: diversity and inclusion in clinical trials round-up
Although there’s been an increase of inflammatory bowel disease (IBD) in underrepresented populations, there are still lots of misconceptions surrounding Crohn’s and ulcerative colitis among certain ethnic groups. ... Different ethnic groups are at
-
News: Living with Ulcerative Colitis and Crohn's Disease
Living with Ulcerative Colitis (UC) and Crohn’s Disease (CD) are new patient syndicated reports which offer valuable insights into patient attitudes and behaviour towards their condition, treatments and unmet needs.
-
Cello Health Insight wins EphMRA’s 2019 Market Research Excellence Award for 'Business Impact through Innovation'
The winning entry focused on exploring the Crohn’s Disease and Ulcerative Colitis patient journeys – mapping the transactional touchpoints and overlaying the emotional experience of patients so that Janssen could gauge
-
emotive adds to medical team with new Scientific Lead and Associate Medical Writer
Kate is experienced in a wide range of therapy areas, including immunology, specifically Crohn’s disease, ulcerative colitis and psoriatic arthritis, in ophthalmology, including retinal diseases, glaucoma and dry eye disease,
More from PMHub
Approximately 5 fully matching, plus 10 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Scientific Strategy Lead, Medical Communications, UK
-
Highly competitive salary
- Medical Writer, MRNA/ Covid 19, Medical Communications, UK
-
Highly competitive salary
- Senior Analyst, Market Access, UK, Home based
-
Highly competitive salary
- Vice President, Medical Communications, UK, six figure package
-
Six figure salary
- Biogen and Happify Health team up to create digital platform for MS patients
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Moderna to launch Innovation and Technology Center in the UK
- Bristol Myers Squibb announces positive trial results for treatment of MS
- Novartis and Precision BioSciences announce in vivo gene editing collaboration
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- Innovative Health Initiative launches first two calls for proposals to tackle ‘biggest’ health research challenges
- NHS App to revolutionise digital health and care with major digital updates by 2023
- Dermavant publishes positive phase 3 data for treatment of plaque psoriasis
- How pharma found its voice – health communications for a brave new world
- The importance of beliefs in creative health engagement
- In recognition of the Anniversary of Stonewall, Nucleus Global brings attention and awareness to persistent health care inequities experienced by LGBTQIA+
- Novo Nordisk and Echosens collaborate to advance early diagnosis of non-alcoholic steatohepatitis
- MSD and AstraZeneca announce phase 3 results for prostate cancer therapy
- Almirall shares positive topline results from atopic dermatitis trials
- Novartis publishes final positive phase 3 results of Zolgensma in Nature Medicine
- Pfizer to buy 8.1% stake in Valneva in support of joint Lyme disease programme
- Research from Imperial College London shows single brain scan could diagnose Alzheimer’s disease
PMHub
The Good Ideas Group
Remarkable but responsible creative work. We're most passionate about the pursuit of original, powerful ideas that our clients can harness...
Latest intelligence
- The Evolving Role of the Sales Rep
- The COVID-19 pandemic sparked an evolution in physician engagement. Jill Padgett, EdD, Head of Training, explores what this means for the sales force and shares her advice for succeeding in...
- Measure your omnichannel maturity with our new tool
- Try our Omnichannel Maturity Tool to gain tangible advice and an instant analysis of your omnichannel readiness....
- Report: Omnichannel advice for the life science industry
- In the latest issue of Delta magazine, Fishawack Health's Medical, Marketing, and Consulting experts share their practical advice for creating meaningful omnichannel stakeholder experiences and reveal our proprietary tool for...
